

Resource Summary Report

Generated by [NIF](#) on Sep 23, 2026

NCI-H292

RRID:CVCL_0455

Type: Cell Line

Proper Citation

RRID:CVCL_0455

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0455

Proper Citation: RRID:CVCL_0455

Description: Cell line NCI-H292 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung mucoepidermoid carcinoma

Defining Citation: [PMID:1311061](#), [PMID:3335022](#), [PMID:8806092](#), [PMID:12539049](#), [PMID:15193437](#), [PMID:17332333](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: African American., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H292

Synonyms: H292, H-292, NCI-HUT-292, Hut292, NCIH292

Cross References: BTO:BTO_0002418, CLO:CLO_0008080, EFO:EFO_0006690, MCCL:MCC:0000353, CLDB:cl3653, CLDB:cl3654, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1848, BCRC:60372, BCRJ:0187, BioSample:SAMN03471312, BioSample:SAMN10988040, cancercellines:CVCL_0455, CCRID:1101HUM-PUMC000233, CCRID:3101HUMSCSP582, CCRID:3101HUMTCHu122,

CCTCC:GDC0211, Cell_Model_Passport:SIDM00493, ChEMBL-Cells:ChEMBL3308637, ChEMBL-Targets:ChEMBL614733, CLS:305040, Cosmic:753604, Cosmic:844598, Cosmic:877404, Cosmic:1017828, Cosmic:1047099, Cosmic:1152499, Cosmic:1188584, Cosmic:1288262, Cosmic:1466803, Cosmic:1519249, Cosmic:1520933, Cosmic:1520947, Cosmic:1870272, Cosmic:1995573, Cosmic:2058648, Cosmic:2630420, Cosmic:2668261, Cosmic-CLP:753604, DepMap:ACH-000474, DepMap:ACH-001075, ECACC:91091815, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:753604, GEO:GSM206489, GEO:GSM274745, GEO:GSM274746, GEO:GSM784237, GEO:GSM794281, GEO:GSM888505, GEO:GSM1670237, GEO:GSM2231213, IARC_TP53:21568, ICLC:HTL96009, KCB:KCB 200822YJ, KCLB:21848, LiGeA:CCLE_170, Lonza:1440, PharmacDB:NCIH292_1103_2019, PRIDE:PXD003086, PRIDE:PXD030304, Progenetix:CVCL_0455, PubChem_Cell_line:CVCL_0455, SKY/M-FISH/CGH:2844, Ubigene:YC-B006, Wikidata:Q54908015

ID: CVCL_0455

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260920T004616+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H292.

Warning: Discontinued: KCLB; 21848

Population: African American., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 535 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(6), 1120.

Ma X, et al. (2026) UFMylation-dependent inhibition of AKT signaling by PHLDA3 in lung adenocarcinoma. Cell reports, 45(4), 117154.

B?dzi?ska A, et al. (2026) The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity. Cell communication and signaling : CCS,

24(1).

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Junttila MR, et al. (2026) Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations. *Cancer research*, 86(3), 759.

Kuganesan N, et al. (2026) A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC. *Science advances*, 12(27), eaed6463.

Raquel-Cunha A, et al. (2025) RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR-targeted therapies. *Molecular oncology*.

Tong X, et al. (2025) Cathepsin C correlates with M2 macrophage infiltration and regulates the tumor growth and metastasis in non-small cell lung cancer. *BMC cancer*, 25(1), 1001.

B?dzi?ska A, et al. (2025) The puzzling regulation of the interferon signaling system by the p53 tumor suppressor protein. *Cellular and molecular life sciences : CMLS*, 82(1), 233.

Liu K, et al. (2025) YWHAG mediated epithelial-mesenchymal transition facilitates tumor progression and metastatic spread in non-small cell lung cancer. *Cellular signalling*, 136, 112139.

Megid RA, et al. (2025) Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling. *Frontiers in molecular biosciences*, 12, 1537523.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Yu J, et al. (2025) PIN1 serves as a prognostic and therapeutic biomarker in lung adenocarcinoma. *Functional & integrative genomics*, 25(1), 121.

Shi H, et al. (2025) ADH1B regulates tumor stemness by activating the cAMP/PKA/CREB1 signaling axis to inhibit recurrence and metastasis of lung adenocarcinoma. *Biochemical and biophysical research communications*, 760, 151681.

Wang Q, et al. (2024) Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer. *Journal of experimental & clinical cancer research : CR*, 43(1), 224.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Huang HY, et al. (2024) Incense-burning smoke ingredient Auramine enhances lincRNA-p21 expression for chemosensitization in p53-mutated non-small cell lung cancer. *Journal*

of hazardous materials, 477, 135105.

Li J, et al. (2024) The role of RASA2 in predicting radioresistance in lung cancer through regulation of p53. Translational lung cancer research, 13(3), 587.

Lakhani NJ, et al. (2024) First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(3), 506.